trending Market Intelligence /marketintelligence/en/news-insights/trending/yebm4ho7utqizc_k5tmxjw2 content esgSubNav
In This List

Eleven Biotherapeutics regains compliance with Nasdaq listing requirements

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Eleven Biotherapeutics regains compliance with Nasdaq listing requirements

Eleven Biotherapeutics Inc. said it regained compliance with Nasdaq Stock Market LLC's $1 minimum bid price listing requirement.

The Cambridge, Mass.-based company received a noncompliance notice from the Nasdaq in December 2017 as the closing bid price of the company's common stock was below $1 per share for 30 consecutive business days.

Nasdaq confirmed that the company regained compliance after the closing bid price for its common stock had been at $1 per share or greater for a minimum of 10 consecutive business days.